Out with the old, in with the new. That's pretty much been the mantra at Illumina
But the new mantra seems to be, "Stick with the old, in with the new." Illumina's sequencing sales continue to grow, and it looks like its microarray business has stabilized. Investors like the new system better; shares of the Stock Advisor pick are up 13% today.
Compare that to competitor Affymetrix
Sequencing gives very specific information about the genome, while microarrays provide more general information about the genome or expression of genes. Microarrays were traditionally used because they could provide a lot of information cheaply. As the price of sequencing has declined, its popularity among researchers has increased.
Illumina doesn't break down the exact ratio of sequencing to microarray products, but microarray consumables still make up more than half of the consumables sold, even though they declined year over year. Combined consumables rose 11% year over year.
The cheaper price of sequencing looks like it's reinvigorating the microarray business. A large consortium is working on sequencing a thousand genomes, which will give researchers plenty to look for in their samples. Illumina is making arrays containing those sequences available as the consortium releases each one. Sales of both microarrays and the machines that read them were up compared to last quarter.
I continue to think that drug companies Pfizer
What will be the next megatrend? Austin Edwards thinks he knows.
More from The Motley Fool
What Happened in the Stock Market Today
On a record day for the indexes, Illumina stock rose on a product announcement and positive outlook, and e.l.f. Beauty fell following a lowered growth forecast.
5 Reasons Illumina Enjoyed a Big J.P. Morgan Conference Bounce
The gene-sequencing leader had plenty of good news to announce at the major healthcare conference this week.
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
Which stock wins in a head-to-head match-up between these two gene-sequencing leaders?